Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 5, 2025. 

NeurologyLive® Friday 5 — September 5, 2025

A recent study reveals that personalized extended interval dosing of natalizumab significantly reduces JCV seroconversion risk in patients with MS.

Personalized Extended Interval Dosing Reduces John Cunningham Virus Seroconversion Rate for Natalizumab

Videos

Experts highlighted the need for clearer treatment sequencing and improved transition of care for patients with LGS from childhood to adulthood. [WATCH TIME: 3 minutes]

Identifying Gaps in Lennox-Gastaut Syndrome Care Across the Lifespan

The head of the neurology department at Vall d’Hebron University Hospital provided perspective on how migraine treatment might advance in the near future, highlighting emerging pathways like PACAP antagonists and long-acting toxins. [WATCH TIME: 3 minutes]

Expanding the Future of Pediatric Migraine Care With Novel Pathways: Patricia Pozo-Rosich, MD, PhD

Co-director, Jane and John Justin Neurosciences Center, Cook Children’s Hospital

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Barry Byrne, MD, PhD. [LISTEN TIME: 15 minutes]

Episode 149: Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne

, has been with the team since September 2022. Follow her on Twitter 

Amaal Starling, MD, FAHS, FAAN, associate professor of neurology at Mayo Clinic College of Medicine, shared data recently presented at AHS 2025 showing that eptinezumab extended the time between migraine attacks.

Analyzing Eptinezumab’s Ability to Extend Interictal Periods and Reduce Migraine Burden

The director of the Neuroethics Program at Cleveland Clinic discussed the evolving role of ethics in neurological clinical trials, highlighting skill development, safeguards, and patient-centered decision-making.

NeuroVoices: Paul Ford, PhD, on Ethical Balance in Complex Clinical Research for Neurology

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAIC 2025

CMSC 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

1rem

David Kudrow, MD, provides a discussion on the available treatment options for migraine management and prevention.

Expert Perspectives on the Management of Acute and Preventative Migraine

David Kudrow, MD, defines episodic and chronic migraine and details how symptoms differ.

The Difference Between Episodic and Chronic Migraine

An expert neurologist explains how to decide on migraine treatment with a patient and when to consider preventive treatment.

Deciding on Acute and Preventative Treatment Options for Migraine

Dr David Kudrow discusses how CGRP antagonist treatments have affected chronic migraine, including the effect on quality of life.

The Impact of CGRP Antagonists on Chronic Migraine

A migraine specialist examines the efficacy and safety of oral CGRP antagonist ubrogepant for the acute treatment of migraine.

Ubrogepant for Acute Migraine Treatment

David Kudrow, MD, reviews the available FDA-approved injectable CGRP antagonists for preventive migraine treatment.

Preventative Migraine Treatment: Injectable CGRP Antagonists

A key opinion leader illustrates how recently approved rimegepant for preventive episodic migraine treatment could change the treatment landscape.

Rimegepant for Preventative Migraine Treatment

Dr David Kudrow shares some advice for community neurologists on the acute and preventive treatment of migraine.

Acute and Preventative Migraine Treatment: Advice for Neurologists